Hims & Hers (HIMS)
Health care services
Close on Nov 10, 2026 (from our latest article): $19.13
- Market value
- $4.5Bat the Nov 10 close
- Revenue growth
- +30%12 months to Sep 30, 2026 (10-Q)
- FCF margin
- 0%12 months to Sep 30, 2026 (10-Q)
- Net debt
- $655Mat Sep 30, 2026
- Worst fall since listing
- −87.3%Feb 8, 2021 to May 11, 2022; back to that high in Jun 2024
About the company
Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)
The Long View
Hims listed in 2021 as an online men’s-health brand and reported $2.35B of revenue in 2025, helped by newer treatments including GLP-1 weight-loss offerings launched in 2024 (10-K 2025, Q2 2024 letter).
▲ better · ▼ worse · ⚠ watch, latest quarter · share count · cash
Updated Nov 11, 2026
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
More of our coverage that names Hims & Hers
Long-term fundamentals
Annual results for Hims & Hers, FY2019–FY2025, as reported in its 10-K filings.
Revenue and free cash flow
Revenue went from $83M in FY2019 to $2.3B in FY2025.
Free cash flow was positive in 3 of the 7 years shown; FY2025: $57M.
Margins
Operating margin was 4% in FY2025, vs −10% in FY2020.
Gross margin was 74% in FY2025, vs 74% in FY2020.
Diluted share count
The diluted share count rose 38% from FY2021 to FY2025, to 258M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $2.3B | 74% | 4% | $128M | $300M | $243M | $57M |
| FY2024 | $1.5B | 79% | 4% | $126M | $251M | $53M | $198M |
| FY2023 | $872M | 82% | −3% | −$24M | $73M | $27M | $47M |
| FY2022 | $527M | 78% | −13% | −$66M | −$27M | $7M | −$34M |
| FY2021 | $272M | 75% | −42% | −$108M | −$34M | $5M | −$39M |
| FY2020 | $149M | 74% | −10% | −$18M | −$2M | $4M | −$7M |
| FY2019 | $83M | 54% | −90% | −$72M | −$75M | $2M | −$77M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 258M | $929M | $973M | $135M | — | $90M |
| FY2024 | 237M | $300M | — | $92M | — | $83M |
| FY2023 | 209M | $221M | — | $66M | — | $2M |
| FY2022 | 205M | $180M | — | $43M | — | $0 |
| FY2021 | 187M | $247M | — | $67M | — | $0 |
| FY2020 | — | $100M | — | $6M | — | $0 |
| FY2019 | — | $2M | — | $8M | — | $0 |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 10, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
- Diluted shares before FY2021 are left out: the earlier counts (before the company's listing or merger) are not comparable.
- Capital spending is the 10-K line tagged "payments to acquire productive assets".
Returns by year
| Year | HIMS | S&P 500 |
|---|---|---|
| 2019 | +1.0%† | +31.5% |
| 2020 | +47.5% | +18.4% |
| 2021 | −55.1% | +28.7% |
| 2022 | −2.1% | −18.1% |
| 2023 | +38.9% | +26.3% |
| 2024 | +171.7% | +25.0% |
| 2025 | +34.3% | +17.9% |
| 2026 to date | −50.7% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. † From the first close after listing (Sep 13, 2019); "—" is before listing. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Healthcare
- IOVA Iovance Down 35.4%
- LEGN Legend Down 16%
- TNGX Tango Therapeutics Down 16.4%
- SLS SELLAS Up 156.4%
- IRTC iRhythm Down 30.7%
- VKTX Viking Therapeutics
Show all 26
- ARWR Arrowhead Down 15.3%
- IBRX ImmunityBio Down 17.7%
- KRYS Krystal Down 11%
- CORT Corcept Therapeutics Down 20.1%
- TGTX TG Therapeutics Up 5.9%
- MDGL Madrigal Down 8.1%
- XNCR Xencor Up 15.9%
- VERA Vera Down 1.2%
- VCYT Veracyte Down 54.3%
- NRIX Nurix Therapeutics Down 38.2%
- AGIO Agios Down 9.9%
- WGS GeneDx Up 4428%
- IMCR Immunocore Up 9.1%
- ALNY Alnylam
- ORIC ORIC Pharmaceuticals Down 32%
- PACB PacBio Down 11.4%
- GMAB Genmab Up 28.3%
- ILMN Illumina Down 18.6%
- IDXX IDEXX Laboratories Up 21.8%
- MRNA Moderna Down 17.6%
Questions about Hims & Hers
- How does Hims & Hers make money?
- It sells treatments online by subscription, for sexual health, hair loss, weight loss, skin, hormones and mental health, plus lab testing. Most revenue is recurring billing paid directly by consumers; 2025 revenue was $2.35 billion, 94% of it in the United States. More in the Long View →
- How does a Hims & Hers treatment reach a customer?
- A customer fills in an online questionnaire. A licensed provider from the company's affiliated medical groups prescribes if appropriate, and the company's own or partner pharmacies ship the product. More in the Long View →
- How important are weight-loss drugs to Hims & Hers?
- Most US revenue came from non-GLP-1 offerings in 2025 and the first nine months of 2026. In 2026 it moved its US weight-loss offering to branded GLP-1 drugs through agreements with Novo Nordisk (March) and Eli Lilly (announced in November), keeping compounded versions on a limited scale. More in the Long View →
- What could slow Hims & Hers' growth?
- Its filings point to regulation and supply: the FTC sued in July 2026 over billing, cancellation and health-data practices, which the company disputes and has moved to dismiss, and the FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B list of bulk ingredients for outsourcing facilities. Drugmakers also control the supply of branded weight-loss drugs, and some offerings depend on one supplier or a few. More in the Long View →
- Where does Hims & Hers operate outside the US?
- In the UK, Australia, Canada, France, Germany, Ireland, Spain and Japan, after acquisitions including Zava, Livewell and Eucalyptus. Countries outside the US were 20% of revenue in the first nine months of 2026, up from 6% in 2025. More in the Long View →
Disclosure: one or more of our editors own shares of Hims & Hers (HIMS) as a long-term investment.